1 / 4

Mission statement

Mission statement. Austrian biomedical research institutions intend to assume leadership within the IMI. This will be achieved by a double-pronged strategy: Positioning and developing of core competences of Austrian research institutions in predictive pharmaco-toxicology.

york
Download Presentation

Mission statement

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Mission statement • Austrian biomedical research institutions intend to assume leadership within the IMI. This will be achieved by a double-pronged strategy: • Positioning and developing of core competences of Austrian research institutions in predictive pharmaco-toxicology. • Proposal to EC of a framework and roadmap of the ECDS as an integrated network by identifying appropriate partners with complementary expertise and by defining their interfaces. • This strategy will enable Austrian researchers to make a valuable contribution to the enhancement of European competitiveness in drug development and to benefit from increased networking and acquisition of funding.

  2. Potential additional benefits • Hosting the headquarter of the ECDS • Increased public awareness at national and European levels • Improved training possibilities and better qualified personnel • Fostering existing and future PPPs and academia-industry partnerships in Austria

  3. Core competences in predictive pharmaco-toxicology • Expertise • Liver pathology and biology • Toxicology • Technology • Drug proteomics (off-target effects) • Tissomics (biomarkers) • Metabolomics (biomarkers) • In silico models • Assets • Biobank (biomarkers)

  4. Next steps • Internal • Summary of discussion (Zatloukal) • National • Funding for consortium formation (BM:BWK, FFG, ABI, RFT) (Herlitschka) • Mouse models (Müller) • Metabolomics (Biocrates) • International • EMEA (Eichler) • Pharmacovigilance (Eichler) • In silico (e.g. Astex; Superti-Furga, Tripos; Hecht, IMGuS; Zatloukal, Gramatica; Schulte-Hermann) • CYPs (Wolf; Schulte-Hermann) • EFPIA • EU

More Related